Target intelligence / Profile preview

YTH N6-methyladenosine RNA-binding protein 1 (YTHDF1)

Target
YTHDF1
Molecular classification
RNA-binding protein, m6A reader protein, Post-transcriptional regulator, Other
01

Overview

YTH N6-methyladenosine RNA-binding protein 1 (YTHDF1) is an m6A reader protein that recognizes N6-methyladenosine (m6A) modifications on RNA, primarily promoting the translation of m6A-modified transcripts by enhancing ribosome recruitment and increasing translation efficiency[1][2][6]. It plays a critical role in regulating post-transcriptional gene expression, affecting both translation and stability of target mRNAs. YTHDF1 is particularly important in cancer progression, functioning as either a tumor promoter or suppressor depending on the specific gene targets and context[1][6]. By interacting with translation machinery and other co-factors such as eukaryotic initiation factors, YTHDF1 modulates cellular responses including cell proliferation, immune response, and possibly response to viral infection[1][2][6][8]. No small-molecule drugs targeting YTHDF1 have been approved, but its central role in mRNA metabolism and cancer makes it a candidate for therapeutic intervention.

Other names
YTH domain-containing family protein 1C20orf21DF1DACA-1FLJ20391Dermatomyositis associated with cancer putative autoantigen 1
02

Mechanism of action

Enhancement of translation initiation and elongation of m6A-modified transcripts Promotion of ribosome occupancy on target mRNAs Regulation of mRNA stability via binding to m6A sites

03

Biological functions

Regulation of mRNA translationRegulation of mRNA stabilityPromotion of ribosomal loading on m6A-modified mRNARegulation of RNA metabolismImmune response modulationAxon guidance
04

Disease associations

Cancer (promotes or suppresses translation of genes involved in tumorigenesis)Infection (e.g., regulation of viral RNA decay)Other
05

Safety considerations

As YTHDF1 controls global translation of m6A-modified RNA, therapeutic inhibition could disrupt essential cellular processes in both healthy and cancerous cellsPotential for off-target effects on non-cancer tissues with high YTHDF1 activity
06

Interacting drugs

None identified in current data (as of 2024, there are no approved or widely reported drugs directly targeting YTHDF1)
07

Biomarkers

Overexpression or altered expression levels may serve as biomarkers for certain cancersMay serve as a prognostic marker in cancer due to its role in cell proliferation and tumorigenesis

Beyond the preview

Go deeper on YTH N6-methyladenosine RNA-binding protein 1 (YTHDF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on YTH N6-methyladenosine RNA-binding protein 1 (YTHDF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call